147 related articles for article (PubMed ID: 19853661)
1. Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers.
Pavese N; Politis M; Tai YF; Barker RA; Tabrizi SJ; Mason SL; Brooks DJ; Piccini P
Neurobiol Dis; 2010 Feb; 37(2):356-61. PubMed ID: 19853661
[TBL] [Abstract][Full Text] [Related]
2. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study.
Pavese N; Andrews TC; Brooks DJ; Ho AK; Rosser AE; Barker RA; Robbins TW; Sahakian BJ; Dunnett SB; Piccini P
Brain; 2003 May; 126(Pt 5):1127-35. PubMed ID: 12690052
[TBL] [Abstract][Full Text] [Related]
3. Huntington's disease progression. PET and clinical observations.
Andrews TC; Weeks RA; Turjanski N; Gunn RN; Watkins LH; Sahakian B; Hodges JR; Rosser AE; Wood NW; Brooks DJ
Brain; 1999 Dec; 122 ( Pt 12)():2353-63. PubMed ID: 10581228
[TBL] [Abstract][Full Text] [Related]
4. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP
Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012
[TBL] [Abstract][Full Text] [Related]
5. Hypothalamic involvement in Huntington's disease: an in vivo PET study.
Politis M; Pavese N; Tai YF; Tabrizi SJ; Barker RA; Piccini P
Brain; 2008 Nov; 131(Pt 11):2860-9. PubMed ID: 18829696
[TBL] [Abstract][Full Text] [Related]
6. Thalamic metabolism and symptom onset in preclinical Huntington's disease.
Feigin A; Tang C; Ma Y; Mattis P; Zgaljardic D; Guttman M; Paulsen JS; Dhawan V; Eidelberg D
Brain; 2007 Nov; 130(Pt 11):2858-67. PubMed ID: 17893097
[TBL] [Abstract][Full Text] [Related]
7. Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease.
van Oostrom JC; Dekker M; Willemsen AT; de Jong BM; Roos RA; Leenders KL
Eur J Neurol; 2009 Feb; 16(2):226-31. PubMed ID: 19138335
[TBL] [Abstract][Full Text] [Related]
8. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease.
Weeks RA; Piccini P; Harding AE; Brooks DJ
Ann Neurol; 1996 Jul; 40(1):49-54. PubMed ID: 8687191
[TBL] [Abstract][Full Text] [Related]
9. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease.
Ginovart N; Lundin A; Farde L; Halldin C; Bäckman L; Swahn CG; Pauli S; Sedvall G
Brain; 1997 Mar; 120 ( Pt 3)():503-14. PubMed ID: 9126061
[TBL] [Abstract][Full Text] [Related]
10. Microglial activation in presymptomatic Huntington's disease gene carriers.
Tai YF; Pavese N; Gerhard A; Tabrizi SJ; Barker RA; Brooks DJ; Piccini P
Brain; 2007 Jul; 130(Pt 7):1759-66. PubMed ID: 17400599
[TBL] [Abstract][Full Text] [Related]
11. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease.
van Oostrom JC; Maguire RP; Verschuuren-Bemelmans CC; Veenma-van der Duin L; Pruim J; Roos RA; Leenders KL
Neurology; 2005 Sep; 65(6):941-3. PubMed ID: 16186542
[TBL] [Abstract][Full Text] [Related]
12. Striatal molecular alterations in HD gene carriers: a systematic review and meta-analysis of PET studies.
Niccolini F; Pagano G; Fusar-Poli P; Wood A; Mrzljak L; Sampaio C; Politis M
J Neurol Neurosurg Psychiatry; 2018 Feb; 89(2):185-196. PubMed ID: 28889093
[TBL] [Abstract][Full Text] [Related]
13. Metabolic network as a progression biomarker of premanifest Huntington's disease.
Tang CC; Feigin A; Ma Y; Habeck C; Paulsen JS; Leenders KL; Teune LK; van Oostrom JC; Guttman M; Dhawan V; Eidelberg D
J Clin Invest; 2013 Sep; 123(9):4076-88. PubMed ID: 23985564
[TBL] [Abstract][Full Text] [Related]
14. Cognitive deficits and striato-frontal dopamine release in Parkinson's disease.
Sawamoto N; Piccini P; Hotton G; Pavese N; Thielemans K; Brooks DJ
Brain; 2008 May; 131(Pt 5):1294-302. PubMed ID: 18362097
[TBL] [Abstract][Full Text] [Related]
15. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes.
Bäckman L; Robins-Wahlin TB; Lundin A; Ginovart N; Farde L
Brain; 1997 Dec; 120 ( Pt 12)():2207-17. PubMed ID: 9448576
[TBL] [Abstract][Full Text] [Related]
16. [11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length.
Antonini A; Leenders KL; Eidelberg D
Ann Neurol; 1998 Feb; 43(2):253-5. PubMed ID: 9485067
[TBL] [Abstract][Full Text] [Related]
17. Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers.
Politis M; Lahiri N; Niccolini F; Su P; Wu K; Giannetti P; Scahill RI; Turkheimer FE; Tabrizi SJ; Piccini P
Neurobiol Dis; 2015 Nov; 83():115-21. PubMed ID: 26297319
[TBL] [Abstract][Full Text] [Related]
18. Abnormal striatal and thalamic dopamine neurotransmission: Genotype-related features of dystonia.
Carbon M; Niethammer M; Peng S; Raymond D; Dhawan V; Chaly T; Ma Y; Bressman S; Eidelberg D
Neurology; 2009 Jun; 72(24):2097-103. PubMed ID: 19528516
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal Small-Animal PET Imaging of the zQ175 Mouse Model of Huntington Disease Shows In Vivo Changes of Molecular Targets in the Striatum and Cerebral Cortex.
Häggkvist J; Tóth M; Tari L; Varnäs K; Svedberg M; Forsberg A; Nag S; Dominguez C; Munoz-Sanjuan I; Bard J; Wityak J; Varrone A; Halldin C; Mrzljak L
J Nucl Med; 2017 Apr; 58(4):617-622. PubMed ID: 27856625
[TBL] [Abstract][Full Text] [Related]
20. Extrastriatal dopamine D(2) receptor binding in Huntington's disease.
Esmaeilzadeh M; Farde L; Karlsson P; Varrone A; Halldin C; Waters S; Tedroff J
Hum Brain Mapp; 2011 Oct; 32(10):1626-36. PubMed ID: 20886576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
